# A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin

> **NCT01333137** · PHASE1 · TERMINATED · sponsor: **Piramal Enterprises Limited** · enrollment: 11 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Gemcitabine and Carboplatin
- **DRUG:** P276-00 along with Gemcitabine and carboplatin

## Key facts

- **NCT ID:** NCT01333137
- **Lead sponsor:** Piramal Enterprises Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-08
- **Primary completion:** 2012-07
- **Final completion:** 2014-03
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2014-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01333137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01333137, "A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01333137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*